A post-hoc analysis of two late-stage trials of Sanofi‘s (NYSE:SNY) Soliqua insulin glargine and lixisenatide injection showed that it provides blood sugar control earlier and in more adults than just insulin glargine, the company reported.
The analysis was presented today at the European Association for the Study of Diabetes in Portugal.
Researchers reviewed data from Phase III trials LixiLan-O and LixiLan-L, comparing the effectiveness of Soliqua and insulin glargine in more than 1,900 adults with Type II diabetes.
More adults using Sanofi’s Soliqua reached blood sugar targets at eight and 12 weeks compared to those receiving insulin glargine, the company said.
“Reaching an HbA1C target quickly can have a benefit for adults with type 2 diabetes,” Dr. Juan Frias, president & principal investigator of the National Research Institute, said in prepared remarks. “Early, effective glycemic control can lead to better outcomes, both clinically and in terms of the overall cost of care.”
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
